Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin

Association Francaise de Chirurgie

Status: Completed

Conditions: Carcinomatosis, Peritoneal

Treatments: Drug: PIPAC with systemic chemotherapy; Drug: Systemic chemotherapy alone

Study type: Observational

Funder types: Other

Identifiers

NCT04879953

PIPAC

Details and patient eligibility

About

Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for the treatment of initially unresectable peritoneal carcinomatosis. The objective of this study was to compare the results of PIPAC associated with systemic chemotherapy with those of systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without metastasis other than peritoneal, and WHO performance status <3.

Enrollment: 46 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients 18 years or over
• Patients with adenocarcinoma-type gastric non-resectable péritonéale carcinomatosis.
• Patients without metastasis other than peritoneal.
• WHO performance status <3
• Patients treated either with PIPAC administered in alternation with systemic chemotherapy (PIPAC_CHEM) or by systemic chemotherapy alone (ONLY_CHEM)
• Patient informed

Exclusion criteria

• Patients opposed

Trial design

46 participants in 2 patient groups

PIPAC CHEM

Description:

PIPAC associated with systemic chemotherapy

Treatment:

Drug: PIPAC with systemic chemotherapy

ONLY CHEM

Description:

systemic chemotherapy alone

Treatment:

Drug: Systemic chemotherapy alone